Judge Leonard P. Stark recently issued a claim construction order relating to two patents claiming once-daily formulations of tetracyclines. Galderma Laboratories Inc., et al. v. Amneal Phamaceuticals, LLC, et al., C.A. No. 11-1106-LPS (D. Del. July 30, 2013). The following claim terms were construed by the Court:
“steady state blood levels of doxycycline of a minimum of 0.1 μg/ml and a maximum of 1.0 μg/ml”
“steady state blood levels of the doxycycline of between 0.3 μg/ml to 0.8 μg/ml”
“pellets”
“pellet”
“coated with at least one enteric polymer”
Delaware IP Law Blog 